Abstract:Despite advances in antimicrobial and anti-inflammatory treatment, inflammation and its consequences remain a major challenge in the field of medicine. Inflammatory reactions can lead to life-threatening conditions such as septic shock, while chronic inflammation has the potential to worsen the condition of body tissues and ultimately lead to significant impairment of their functionality. Although the central nervous system has long been considered immune privileged to peripheral immune responses, recent research has shown that strong immune responses in the periphery also affect the brain, leading to reactive microglia, which belong to the innate immune system and reside in the brain, and neuroinflammation. The inflammatory response is primarily a protective mechanism to defend against pathogens and tissue damage. However, excessive and chronic inflammation can have negative effects on neuronal structure and function. Neuroinflammation underlies the pathogenesis of many neurological and neurodegenerative diseases and can accelerate their progression. Consequently, targeting inflammatory signaling pathways offers potential therapeutic strategies for various neuropathological conditions, particularly Parkinson's and Alzheimer's disease, by curbing inflammation. Here the blood–brain barrier is a major hurdle for potential therapeutic strategies, therefore it would be highly advantageous to foster and utilize brain innate anti-inflammatory mechanisms. The tricarboxylic acid cycle-derived metabolite itaconate is highly upregulated in activated macrophages and has been shown to act as an immunomodulator with anti-inflammatory and antimicrobial functions. Mesaconate, an isomer of itaconate, similarly reduces the inflammatory response in macrophages. Nevertheless, most studies have focused on its esterified forms and its peripheral effects, while its influence on the CNS remained largely unexplored. Therefore, this study investigated the immunomodulatory and therapeutic potential of endogenously synthesized itaconate and its isomer mesaconate in lipopolysaccharide (LPS)-induced neuroinflammatory processes. Our results show that both itaconate and mesaconate reduce LPS-induced neuroinflammation, as evidenced by lower levels of inflammatory mediators, reduced microglial reactivity and a rescue of synaptic plasticity, the cellular correlate of learning and memory processes in the brain. Overall, this study emphasizes that both itaconate and mesaconate have therapeutic potential for neuroinflammatory processes in the brain and are of remarkable importance due to their endogenous origin and production, which usually leads to high tolerance.

Dimethyl itaconate modulates neuroprotective effect on primary rat astrocytes under inflammatory condition by regulating the expression of neurotrophic factors and TrkA/B-P75 receptors

Dimethyl Itaconate Inhibits Neuroinflammation to Alleviate Chronic Pain in Mice.

Itaconate as a Promising Therapy for Neuropathic Pain and Inflammatory Pain

Dexmedetomidine inhibits lipopolysaccharide-in duced inflammatory response in hippocampal astrocytes in vitro

Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture

The potential therapeutic role of itaconate and mesaconate on the detrimental effects of LPS-induced neuroinflammation in the brain

Methylenedioxy Piperamide-Derived Compound D5 Regulates Inflammatory Cytokine Secretion in a Culture of Human Glial Cells

Effects of MRP8, LPS, and Lenalidomide on the Expressions of TNF-α , Brain-Enriched, and Inflammation-Related Micrornas in the Primary Astrocyte Culture.

Ameliorative effects of Diammonium Glycyrrhizinate on inflammation in focal cerebral ischemic-reperfusion injury

Inhibition of PI3Kγ by AS605240 Protects Tmcao Mice by Attenuating Pro-Inflammatory Signaling and Cytokine Release in Reactive Astrocytes

Akebia saponin D protects hippocampal neurogenesis from microglia-mediated inflammation and ameliorates depressive-like behaviors and cognitive impairment in mice through the PI3K-Akt pathway

Dihydromyricetin attenuates inflammation through TLR4/NF-kappaB pathway

Effect of the AMPK activator AICAR on inhibiting the inflammatory response of astrocytes and protecting the neurons from injury after oxygen-glucose deprivation treatment

Neuroprotective Effects of Dammarane Sapogenins Against lipopolysaccharide-induced Cognitive Impairment, Neuroinflammation and Synaptic Dysfunction

The Effect of Dexmedetomidine Post-treatment on the Inflammatory Response of Astrocyte Induced by Lipopolysaccharide

Dihydroartemisinin ameliorates LPS-induced neuroinflammation by inhibiting the PI3K/AKT pathway

Sesquiterpene dimer (DSF-52) from Artemisia argyi inhibits microglia-mediated neuroinflammation via suppression of NF-κB, JNK/p38 MAPKs and Jak2/Stat3 signaling pathways

Effect of imatinib on lipopolysaccharide‑induced acute lung injury and endothelial dysfunction through P38 MAPK and NF-κB signaling pathway in vivo and in vitro

IGF-1 receptor is involved in the regulatory effects of icariin and icaritin in astrocytes under basal conditions and after an inflammatory challenge

Effect of Aster Tataricus on Production of Inflammatory Mediators in LPS Stimulated Rat Astrocytoma Cell Line (C6) and THP-1 Cells

Reactive Astrocytes Display Pro-inflammatory Adaptability with Modulation of Notch-PI3K-AKT Signaling Pathway Under Inflammatory Stimulation